gene

FUS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about FUS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2389Connections

16Hypotheses

5Analyses

50Outgoing

50Incoming

10Experiments

6Debates

Summary

FUS is a gene implicated in neurodegeneration research. Key relationships include: associated with, therapeutic target, interacts with. Associated with AD, ALI, ALS. Connected to 507 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	FUS
Full Name	Fused in Sarcoma
Chromosome	16p11.2.
Protein Type	Protein
Function	is an important component in the neurobiology of neurodegenerative diseases.
Pathways	Blood-Brain Barrier, Hippo Pathway, Oxidative Stress, Sod1, Tdp-43
UniProt ID	Search UniProt
GeneCards	FUS
Human Protein Atlas	FUS
Associated Diseases	AD, Aging, ALI, Als, Alzheimer
Known Drugs/Compounds	ADUCANUMAB, Antisense Oligonucleotide, Rna Oligonucleotides, RNA oligonucleotides
Interactions	ACTB, Actin, AD, AGING, ALPHA-SYNUCLEIN, ALS
SciDEX Hypotheses	ASO-Mediated Exon Skipping to Restore FUS-TAZ Chap FUS Mutations Alter Stress Granule Material Proper FUS Mutations Impede G3BP1's Chaperone Function, E
KG Connections	1547 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure Comparison — FUS Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

4FDD — X-ray / Cryo-EM

🔮 AI Predicted Structure

P35637 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (16)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

flowchart TD
    FUS(["FUS"])
    TARDBP(["TARDBP"])
    Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    ALS(["ALS"])
    AMYOTROPHIC_LATERAL_SCLEROSIS(["AMYOTROPHIC LATERAL SCLEROSIS"])
    Als["Als"]
    SOD1(["SOD1"])
    MECP2(["MECP2"])
    GENES(["GENES"])

    FUS -->|"associated with"| TARDBP
    FUS -->|"associated with"| Amyotrophic_Lateral_Sclerosis
    ALS -->|"associated with"| FUS
    FUS -->|"risk factor for"| Amyotrophic_Lateral_Sclerosis
    FUS -->|"associated with"| AMYOTROPHIC_LATERAL_SCLEROSIS
    FUS -->|"interacts with"| Amyotrophic_Lateral_Sclerosis
    FUS -->|"associated with"| Als
    FUS -->|"causes"| Amyotrophic_Lateral_Sclerosis
    FUS -->|"associated with"| SOD1
    FUS -->|"regulates"| MECP2
    FUS -->|"interacts with"| ALS
    FUS -->|"activates"| ALS
    FUS -->|"associated with"| GENES
    FUS -->|"associated with"| ALS
    FUS -->|"interacts with"| AMYOTROPHIC_LATERAL_SCLEROSIS

    style FUS fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (1220)

Target	Relation	Type	Str
Amyotrophic Lateral Sclerosis	associated_with	disease	1.00
TARDBP	associated_with	gene	1.00
DEMENTIA	associated_with	disease	0.98
Stress Granule Transcriptome	modulates	phenotype	0.95
liquid phase condensation	involved_in	process	0.95
TDP-43	interacts_with	gene	0.95
Neurodegeneration	associated_with	process	0.95
Phase Transition	involved_in	process	0.95
FTD	associated_with	disease	0.95
ALS	associated_with	disease	0.95
Early-Onset ALS	risk_factor_for	phenotype	0.93
oxidative stress response	participates_in	pathway	0.90
Cytoplasmic Accumulation	involved_in	process	0.90
TAU	associated_with	gene	0.90
Motor Neuron Degeneration	causes	disease	0.90
Ftld-Fet	component_of	disease	0.90
biomolecular condensates	component_of	mechanism	0.90
HSPA8 mRNA Dendritic Localization	regulates	process	0.90
pathological aggregation	involved_in	process	0.90
Histone H1.2	interacts_with	protein	0.90
Fibrillization	involved_in	process	0.90
Stress Granules	interacts_with	process	0.90
Nuclear Localization	involved_in	process	0.90
HSPA8	regulates	gene	0.90
H1F2	interacts_with	protein	0.90
protein misfolding	causes	pathway	0.90
Motor Neuron Degeneration	contributes_to	process	0.90
Neuromuscular Synapses	regulates	phenotype	0.90
Stress Granules	associated_with	process	0.90
motor neuron death	contributes_to	process	0.90
circEHD2	regulates	gene	0.90
Amyotrophic Lateral Sclerosis	biomarker_for	disease	0.90
FRONTOTEMPORAL DEMENTIA	associated_with	disease	0.90
Proteostasis	regulates	process	0.90
frontotemporal dementia	associated_with	disease	0.90
NEURON	associated_with	gene	0.90
Cytoplasmic Mislocalization	associated_with	phenotype	0.90
Pathological Aggregation	associated_with	phenotype	0.90
AMYOTROPHIC LATERAL SCLEROSIS	associated_with	gene	0.90
cytoplasmic mislocalization	involved_in	process	0.88
Glucose Oxidation	regulates	process	0.85
Als	associated_with	disease	0.85
Histone Post-Translational Modification	regulates	process	0.85
RNA metabolism	regulates	process	0.85
Myogenesis	regulates	process	0.85
PARylation	involved_in	process	0.85
Rna-Binding Proteins	interacts_with	protein	0.85
Amyotrophic Lateral Sclerosis	interacts_with	disease	0.85
Motor Neuron Degeneration	involved_in	process	0.85
Central Nervous System	expressed_in	brain_region	0.85

Incoming (1169)

Source	Relation	Type	Str
entities-histone-modifications	interacts_with	wiki	0.00
entities-mitochondrial-dynamics	interacts_with	wiki	0.00
ALS	associated_with	disease	1.00
RNA oligonucleotides	binds	compound	0.90
Rna Oligonucleotides	interacts_with	compound	0.90
Rna Oligonucleotides	inhibits	compound	0.90
RNA oligonucleotides	targets	compound	0.85
Mistranslation	exacerbates	process	0.85
KAPB2	interacts_with	protein	0.85
DIPEPTIDE REPEAT PROTEINS	interacts_with	protein	0.85
ALS	interacts_with	entity	0.82
Antisense Oligonucleotide	therapeutic_target	drug	0.80
Chronological Ageing	modulates	process	0.80
ALS	accumulates_in	gene	0.80
DNA	disrupts	gene	0.80
Stress Granules	mediates	process	0.80
MATR3	interacts_with	protein	0.75
ALS	activates	disease	0.74
ALZHEIMER'S DISEASE	associated_with	disease	0.72
FTD	associated_with	disease	0.70
ACHE	associated_with	gene	0.70
AMYOTROPHIC LATERAL SCLEROSIS	transports	disease	0.70
BACE1	interacts_with	gene	0.70
APP	interacts_with	gene	0.70
ATG5	regulates	gene	0.70
APOE	mediates	gene	0.70
C9ORF72	associated_with	gene	0.70
entities-c9orf72-protein	interacts_with	wiki	0.70
C9ORF72	interacts_with	gene	0.70
NEURODEGENERATION	therapeutic_target	gene	0.70
IFN	associated_with	gene	0.70
DNA	causes	gene	0.70
MICRORNAS	modulates	gene	0.70
DNA	accumulates_in	gene	0.70
GAIN	causes	gene	0.70
ALZHEIMER	associated_with	gene	0.65
UBIQUITIN	associated_with	protein	0.65
TDP-43	phosphorylates	gene	0.65
FRONTOTEMPORAL DEMENTIA	interacts_with	disease	0.65
CORTEX	transports	brain_region	0.65
CORTEX	regulates	brain_region	0.65
AMYOTROPHIC LATERAL SCLEROSIS	causes	disease	0.65
FRONTAL	regulates	brain_region	0.65
INFLAMMATION	inhibits	gene	0.60
YAP	activates	gene	0.60
NEURODEGENERATIVE DISEASES	expressed_in	gene	0.60
NEURODEGENERATION	expressed_in	gene	0.60
AND	expressed_in	gene	0.60
MATR3	contributes_to	gene	0.60
AGING	associated_with	gene	0.60

Targeting Hypotheses (16)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Optogenetic viral vector delivery via tFUS-mediated blood-br	0.846	Alzheimer's disease	Circuit-level neural dynamics in neurode
VHH-Fc Fusion Constructs with Separate BBB-Targeting Moiety	0.750	neurodegeneration	Blood-brain barrier antibody transport m
H3: G3BP1 as Nucleation Hub for TDP-43/FUS Seeding	0.743	neurodegeneration	How do pathological stress granules tran
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis	0.720	neurodegeneration	How does FUS loss-of-function in TAZ reg

LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Tr	0.650	neurodegeneration	Blood-brain barrier antibody transport m
Autophagosome-Lysosome Fusion Defects as Primary Driver of α	0.630	neurodegeneration	Gap 006 analysis (archived stub)
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m	0.621	neurodegeneration	Mitochondrial transfer between astrocyte
FUS Mutations Alter Stress Granule Material Properties to Co	0.613	neurodegeneration	How do pathological stress granules in n
Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-	0.600	neurodegeneration	What are the neuron-specific effects of
Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion	0.583	neurodegeneration	View
Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytos	0.550	drug delivery	Can IGFBPL1 therapeutics effectively cro
GPP Repeat Peptide-Fc Fusion for Enhanced Brain Penetration	0.550	neurodegeneration	Blood-brain barrier antibody transport m
FUS-ALS-Specific Ferroptosis Vulnerability Through NCOA4-Med	0.480	-	Ferroptosis in ALS and motor neuron dise
Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α	0.470	neurodegeneration	What are the optimal oxygen pressure, du
FUS Mutations Impede G3BP1's Chaperone Function, Exposing Ne	0.430	neurodegeneration	How do disease-associated mutations in G

Mentioning Analyses (5)

Scientific analyses that reference this entity

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.720

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.584

How do host cell factors influence the conformation and propagation properties o

neurodegeneration | 2026-04-08 | 0 hypotheses

RNA binding protein dysregulation across ALS FTD and AD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.720

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (10)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
s:** - Test MCU overexpression specifically in layer II neurons in hea	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$200,000
Proposed experiment from debate on Mitochondrial transfer between astr	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Proposed experiment from debate on Mitochondrial transfer between astr	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
AAV-LRRK2 IND-Enabling Study Design	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000
Axonal Transport Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000
Gap Junction Dysfunction Validation in Parkinson's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
AAV-LRRK2 Gene Therapy IND-Enabling Study Design	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson'	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro	validation	Neurodegeneration	0.400	0.50	human	proposed	$3,000,000
Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000

Related Papers (15)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
KIF5A de novo mutation associated with myoclonic seizures and neonatal onset pro [PMID:27414745]	Rydzanicz M, Jagła M, Kosinska J, Tomasi	Clin Genet	2017	1
TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and [PMID:23395375]	van Spronsen M, Mikhaylova M, Lipka J, S	Neuron	2013	1
Delineation of the TRAK binding regions of the kinesin-1 motor proteins. [PMID:24161670]	Randall TS, Moores C, Stephenson FA	FEBS Lett	2013	1
Therapeutic developments in pancreatic cancer. [PMID:37798442]	["Hu Z", "O'Reilly E"]	Nature reviews. Gastroenterolo	2024	0
Defining treatment-resistant depression. [PMID:31638723]	["Gaynes B", "Lux L", "Gartlehner G", "A	Depression and anxiety	2020	0
Emerging trends in global freshwater availability. [PMID:29769728]	["Rodell M", "Famiglietti J", "Wiese D",	Nature	2018	0
Acute Heart Failure: Definition, Classification and Epidemiology. [PMID:28785969]	["Kurmani S", "Squire I"]	Current heart failure reports	2017	0
Invasive ductal carcinoma: relationship between pathological characteristics and [PMID:28658335]	["Aquino R", "Vasques P", "Cavalcante D"	Revista do Colegio Brasileiro	2017	0
The Impact of Intergenerational Cultural Dissonance on Alcohol Use Among Vietnam [PMID:26598062]	["Kane J", "Johnson R", "Robinson C", "J	The Journal of adolescent heal	2016	0
A proliferative burst during preadolescence establishes the final cardiomyocyte [PMID:24813607]	["Naqvi N", "Li M", "Calvert J", "Tejada	Cell	2014	0
Family medicine match rate increases slightly. [PMID:22585896]	Sheri Porter	Annals of family medicine	2012	0
Human plasma glycome in attention-deficit hyperactivity disorder and autism spec [PMID:20974899]	["Pivac N", "Knezevi\u0107 A", "Gornik O	Molecular & cellular proteomic	2011	0
The Crumbs complex: from epithelial-cell polarity to retinal degeneration. [PMID:19625503]	["Bulgakova N", "Knust E"]	Journal of cell science	2009	0
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell [PMID:18971423]	["Landsman L", "Bar-On L", "Zernecke A",	Blood	2009	0
GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain proteins [PMID:15644324]	Brickley K, Smith MJ, Beck M, Stephenson	The Journal of biological chem	2005	0

Debates (6)

Multi-agent debates referencing this entity

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate

closed · Rounds: 4 · Score: 0.81 · 2026-04-16

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

closed · Rounds: 4 · Score: 0.63 · 2026-04-13

RNA binding protein dysregulation across ALS FTD and AD

closed · Rounds: 4 · Score: 0.72 · 2026-04-12

How do host cell factors influence the conformation and propagation properties o

closed · Rounds: 4 · Score: 0.95 · 2026-04-10

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

RNA binding protein dysregulation across ALS FTD and AD

closed · Rounds: 4 · Score: 0.88 · 2026-04-06

Related Research

Hypotheses and analyses mentioning FUS in their description or question text

FUS

Understanding Entity Pages

Summary

Wiki Pages (16)

FUS — Fused in Sarcoma

FUS Gene-Mechanism-Therapy Causal Chain — ALS/FTD

FUS Mutations in Amyotrophic Lateral Sclerosis

FUS Protein in Amyotrophic Lateral Sclerosis

FUS (Fused in Sarcoma) Protein

FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis

FUS Proteinopathy in Frontotemporal Dementia

FUS Proteinopathy Neurons

FUS Protein

FUS Proteinopathy Pathway in ALS

FUS Proteinopathy

FUS Protein (Fused in Sarcoma)

FUS Protein-Targeting Therapy for ALS/FTD

FUS (Redirect)

Fused in Sarcoma (FUS) Protein

FUS-Mutant Motor Neurons

Pathway Diagram

Outgoing (1220)

Incoming (1169)

Targeting Hypotheses (16)

Mentioning Analyses (5)

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

How do host cell factors influence the conformation and propagation properties o

RNA binding protein dysregulation across ALS FTD and AD

Blood-brain barrier transport mechanisms for antibody therapeutics

Experiments (10)

Related Papers (15)

Debates (6)

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

RNA binding protein dysregulation across ALS FTD and AD

How do host cell factors influence the conformation and propagation properties o

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

RNA binding protein dysregulation across ALS FTD and AD

Related Research

LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Transcytosis

Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagati

Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial deliver

FUS Mutations Alter Stress Granule Material Properties to Confer Autophagy Resis

Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-17, blocking autopha

Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Intern

Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytosis

GPP Repeat Peptide-Fc Fusion for Enhanced Brain Penetration

FUS-ALS-Specific Ferroptosis Vulnerability Through NCOA4-Mediated Ferritinophagy

Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α to enhance VEGF-med

FUS Mutations Impede G3BP1's Chaperone Function, Exposing Neurotoxic Stress Gran